Organogenesis (ORGO) Competitors

Organogenesis logo
$0.81 +0.01 (+1.06%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.80 -0.01 (-1.18%)
As of 07:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ORGO vs. PRTA, TECX, IRD, ALEC, and PBYI

Should you buy Organogenesis stock or one of its competitors? Organogenesis's main competitors and comparable companies include Prothena (PRTA), Tectonic Therapeutic (TECX), Opus Genetics (IRD), Alector (ALEC), and Puma Biotechnology (PBYI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Organogenesis compare to Prothena?

Organogenesis (NASDAQ:ORGO) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Organogenesis presently has a consensus price target of $4.33, indicating a potential upside of 433.92%. Prothena has a consensus price target of $20.00, indicating a potential upside of 142.13%. Given Organogenesis' higher probable upside, equities analysts clearly believe Organogenesis is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organogenesis
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Prothena
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.86

Organogenesis has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Prothena has a beta of -0.2, meaning that its share price is 120% less volatile than the broader market.

Organogenesis has a net margin of -39.34% compared to Prothena's net margin of -45.44%. Prothena's return on equity of -9.98% beat Organogenesis' return on equity.

Company Net Margins Return on Equity Return on Assets
Organogenesis-39.34% -55.28% -23.72%
Prothena -45.44%-9.98%-9.08%

Organogenesis has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$564.17M0.19$37.03M-$1.22N/A
Prothena$9.68M43.82-$244.09M-$0.48N/A

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Prothena had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Prothena and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.05 beat Prothena's score of 0.70 indicating that Organogenesis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organogenesis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Prothena
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Prothena beats Organogenesis on 9 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tectonic Therapeutic currently has a consensus price target of $69.17, indicating a potential upside of 244.46%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 433.92%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than Tectonic Therapeutic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tectonic Therapeutic
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.80
Organogenesis
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Organogenesis has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tectonic TherapeuticN/AN/A-$74.15M-$4.63N/A
Organogenesis$564.17M0.19$37.03M-$1.22N/A

Tectonic Therapeutic has a net margin of 0.00% compared to Organogenesis' net margin of -39.34%. Tectonic Therapeutic's return on equity of -37.69% beat Organogenesis' return on equity.

Company Net Margins Return on Equity Return on Assets
Tectonic TherapeuticN/A -37.69% -35.65%
Organogenesis -39.34%-55.28%-23.72%

Tectonic Therapeutic has a beta of 3.51, suggesting that its share price is 251% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

In the previous week, Organogenesis had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 2 mentions for Organogenesis and 1 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.40 beat Organogenesis' score of 1.05 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tectonic Therapeutic
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Organogenesis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Tectonic Therapeutic beats Organogenesis on 9 of the 15 factors compared between the two stocks.

How does Organogenesis compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Organogenesis has a net margin of -39.34% compared to Opus Genetics' net margin of -1,726.70%. Opus Genetics' return on equity of 0.00% beat Organogenesis' return on equity.

Company Net Margins Return on Equity Return on Assets
Opus Genetics-1,726.70% N/A -134.07%
Organogenesis -39.34%-55.28%-23.72%

Organogenesis has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opus Genetics$14.20M27.57-$49.59M-$1.56N/A
Organogenesis$564.17M0.19$37.03M-$1.22N/A

In the previous week, Opus Genetics had 16 more articles in the media than Organogenesis. MarketBeat recorded 18 mentions for Opus Genetics and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.05 beat Opus Genetics' score of 0.21 indicating that Organogenesis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Opus Genetics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Organogenesis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Opus Genetics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Opus Genetics currently has a consensus price target of $13.29, indicating a potential upside of 228.04%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 433.92%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than Opus Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opus Genetics
1 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.89
Organogenesis
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Organogenesis beats Opus Genetics on 10 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Alector?

Organogenesis (NASDAQ:ORGO) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Alector had 5 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Alector and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.05 beat Alector's score of 1.05 indicating that Organogenesis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organogenesis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alector
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 8.3% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Organogenesis has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Alector has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Organogenesis currently has a consensus target price of $4.33, indicating a potential upside of 433.92%. Alector has a consensus target price of $5.10, indicating a potential upside of 99.22%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Alector.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organogenesis
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43

Alector has a net margin of 23.87% compared to Organogenesis' net margin of -39.34%. Alector's return on equity of 112.21% beat Organogenesis' return on equity.

Company Net Margins Return on Equity Return on Assets
Organogenesis-39.34% -55.28% -23.72%
Alector 23.87%112.21%18.37%

Organogenesis has higher revenue and earnings than Alector. Organogenesis is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$564.17M0.19$37.03M-$1.22N/A
Alector$21.05M18.11-$142.93M$0.357.31

Summary

Alector beats Organogenesis on 10 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Organogenesis has higher revenue and earnings than Puma Biotechnology. Organogenesis is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$228.40M1.62$31.11M$0.4615.52
Organogenesis$564.17M0.19$37.03M-$1.22N/A

Puma Biotechnology has a net margin of 10.26% compared to Organogenesis' net margin of -39.34%. Puma Biotechnology's return on equity of 17.50% beat Organogenesis' return on equity.

Company Net Margins Return on Equity Return on Assets
Puma Biotechnology10.26% 17.50% 11.83%
Organogenesis -39.34%-55.28%-23.72%

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 18.8% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Puma Biotechnology had 5 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Puma Biotechnology and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.05 beat Puma Biotechnology's score of 0.50 indicating that Organogenesis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Puma Biotechnology
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Organogenesis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Puma Biotechnology has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Puma Biotechnology currently has a consensus price target of $6.00, indicating a potential downside of 15.97%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 433.92%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than Puma Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Organogenesis
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Puma Biotechnology beats Organogenesis on 9 of the 14 factors compared between the two stocks.

Get Organogenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGO vs. The Competition

MetricOrganogenesisBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$104.24M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7134.3428.32
Price / Sales0.1915.788.495.70
Price / Cash1.2422.9521.0121.90
Price / Book0.884.184.453.72
Net Income$37.03M-$24.15M$3.52B$393.10M
7 Day Performance-22.70%-7.81%-5.93%-5.77%
1 Month Performance-18.82%-5.99%-4.58%-7.14%
1 Year Performance-85.30%-8.09%-1.94%-7.46%

Organogenesis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGO
Organogenesis
1.6811 of 5 stars
$0.81
+1.1%
$4.33
+433.9%
-86.5%$104.24M$564.17MN/A854
PRTA
Prothena
2.8894 of 5 stars
$7.79
-2.3%
$20.00
+156.9%
-19.4%$399.97M$9.68MN/A67
TECX
Tectonic Therapeutic
2.7087 of 5 stars
$20.15
-4.0%
$69.17
+243.3%
+9.2%$399.58MN/AN/A60
IRD
Opus Genetics
3.1784 of 5 stars
$3.99
-1.2%
$13.29
+232.9%
+132.8%$386.04M$7.91MN/A28
ALEC
Alector
4.6772 of 5 stars
$2.55
-1.0%
$5.10
+100.4%
+106.5%$378.90M$21.05M7.27103

Related Companies and Tools


This page (NASDAQ:ORGO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners